# A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer

> **NCT06292689** · PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Vulvar and Vaginal Cancer

## Interventions

- **DRUG:** Cardunolizumab

## Key facts

- **NCT ID:** NCT06292689
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-22
- **Primary completion:** 2026-03-22
- **Final completion:** 2027-03-22
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-11-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06292689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06292689, "A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06292689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*